Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

If generative AI could contribute in the slightest to such discoveries—as has been promised since the start of the AI boom—where would the technology ... company pioneering AI-driven drug ...

Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Drivers for innovative, non-invasive delivery include improvement ... companies must be able to consistently demonstrate the value that their combination of drugs and delivery technology brings ...

About a third of semaglutide users achieved both inflammation reduction and scarring improvement, more than double compared to those taking the placebo. The drug also helped participants with weight ...

Portal’s technology has a broad range of applications, from drug screening and discovery to advanced cell engineering for research and therapeutic purposes. Despite being only 2 years old, the company ...

Technological advancements in cardiac ablation, including improvements in catheter designs, ablation energy sources such as radiofrequency and cryoablation, and the introduction of innovative mapping ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

"Our goal is to reduce respiratory healthcare carbon emissions without restricting patient choice or risking improvement in health outcomes.” AstraZeneca also released its company-wide ...

A new longevity report by Iris Ventures argues that people of all age groups are taking action, eating the rainbow and relying on vitamins, supplements and natural compounds to live longer and ...

According to statistics published by the World Health Organization (WHO) in 2025, cardiovascular diseases (CVDs) are the ...

Q1 2025 Earnings Call Transcript May 7, 2025 Vishay Intertechnology, Inc. reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Good day, and thank ...